Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

被引：0
|
作者：
Chay, J. [1 ]
Su, R. [1 ]
Tung, J. Y. M. [2 ]
Aslim, E. J. [2 ]
Wong, C. [3 ]
Swan, G.
Chua, W. J. [4 ]
Ho, S. S. H. [2 ]
Finkelstein, E. A. [1 ]
机构：
[1] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
[3] Boston Sci, Asia Pacific, Hlth Econ & Market Access, Singapore, Singapore
[4] Natl Univ Singapore Hosp, Dept Urol, Singapore, Singapore
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0034
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF SEQUENTIAL FIRST- AND SECOND-LINE TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-WORLD DATA AND A PATIENT-LEVEL SIMULATION MODEL
    de Groot, S.
    Blommestein, H.
    Redekop, W.
    Oosterwijk, E.
    Kiemeney, L.
    Uyl-de Groot, C.
    VALUE IN HEALTH, 2013, 16 (07) : A587 - A587
  • [22] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    CRITICAL CARE MEDICINE, 2020, 48
  • [23] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [24] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [26] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [27] Can an Algorithm Select First- and Second-Line Antidepressant Treatments in Primary Care?
    Chekroud, Adam
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S101 - S101
  • [28] COST-EFFECTIVENESS OF AFATINIB AND ERLOTINIB AS SECOND-LINE TREATMENTS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG IN CHINA
    Zhu, J.
    Ye, M.
    Fu, J.
    Wu, B.
    Chu, Y.
    Zhao, Y.
    Zhang, Y.
    Kuo, D.
    Su, B.
    VALUE IN HEALTH, 2017, 20 (09) : A442 - A442
  • [29] Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
    De Groot, S.
    Blommestein, H. M.
    Redekop, W. K.
    Sleijfer, S.
    Kiemeney, L. A. L. M.
    Oosterwijk, E.
    Uyl-de Groot, C. A.
    PLOS ONE, 2017, 12 (05):
  • [30] Interferon-α: alternative first- or second-line therapeutic option for polycythaemia vera
    Mascarenhas, John
    LANCET HAEMATOLOGY, 2020, 7 (03): : E178 - E179
12345